[go: up one dir, main page]

UY28035A1 - Formulaciones de liberacion prolongada en forma de suspension - Google Patents

Formulaciones de liberacion prolongada en forma de suspension

Info

Publication number
UY28035A1
UY28035A1 UY28035A UY28035A UY28035A1 UY 28035 A1 UY28035 A1 UY 28035A1 UY 28035 A UY28035 A UY 28035A UY 28035 A UY28035 A UY 28035A UY 28035 A1 UY28035 A1 UY 28035A1
Authority
UY
Uruguay
Prior art keywords
suspension
prolonged release
release formulations
preparing
release formulation
Prior art date
Application number
UY28035A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28035A1 publication Critical patent/UY28035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un kit farmacéutico para preparar una formulación de liberación prolongada inyectable de un compuesto farmacéutico arilheterocíclico tal como ziprasidona y un procedimiento para preparar dicha formulación de liberación prolongada.
UY28035A 2002-10-25 2003-10-22 Formulaciones de liberacion prolongada en forma de suspension UY28035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42129502P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
UY28035A1 true UY28035A1 (es) 2004-05-31

Family

ID=32176696

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28035A UY28035A1 (es) 2002-10-25 2003-10-22 Formulaciones de liberacion prolongada en forma de suspension

Country Status (21)

Country Link
US (1) US20040146562A1 (es)
EP (1) EP1562546A1 (es)
JP (2) JP2006505579A (es)
KR (1) KR20050071611A (es)
CN (1) CN1703198A (es)
AR (1) AR041826A1 (es)
AU (1) AU2003267763A1 (es)
BR (1) BR0315663A (es)
CA (1) CA2498276A1 (es)
GT (1) GT200300227A (es)
MX (1) MXPA05004299A (es)
NL (1) NL1024616C (es)
NO (1) NO20051187L (es)
PA (1) PA8586301A1 (es)
PE (1) PE20040471A1 (es)
PL (1) PL375603A1 (es)
RU (1) RU2292207C2 (es)
TW (1) TW200418477A (es)
UY (1) UY28035A1 (es)
WO (1) WO2004037224A1 (es)
ZA (1) ZA200501979B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
BR0313602A (pt) 2002-08-20 2005-06-21 Bristol Myers Squibb Co Método e formulação de complexo de aripiprazol
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
WO2004100955A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2006000913A1 (en) * 2004-06-23 2006-01-05 Pfizer Products Inc. Method for sterile filtration of viscous pharmaceutical compositions
PT1809329E (pt) * 2004-09-17 2012-03-29 Durect Corp Composição anestésica local prolongada contendo aibs
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
EP2018151A4 (en) * 2006-05-09 2012-07-18 Astrazeneca Ab STERILIZED PARENTERAL FORMULATION WITH PROTONED PUMP INHIBITOR BY IONIZING RADIATION IN THE END TANK
EP2484347A1 (en) 2006-11-03 2012-08-08 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
US11197850B2 (en) * 2017-02-23 2021-12-14 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331755B2 (en) * 1987-09-07 2003-02-05 Teijin Limited Medicine-containing fat emulsion of the type prepared immediately before use and process for preparing medicine-containing fat emulsion
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
PT811386E (pt) * 1996-05-07 2004-12-31 Pfizer Metodo de seleccao de um sal para a preparacao de um complexo de inclusao
CA2275587C (en) * 1996-12-20 2006-10-24 Alza Corporation Injectable depot gel composition and method of preparing the composition
CA2289196C (en) * 1997-05-16 2007-08-07 Amgen Inc. Sustained-release delayed gels
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AP1409A (en) * 1999-05-27 2005-06-13 Pfizer Prod Inc Ziprasidone suspension.
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1463830A4 (en) * 2001-08-31 2006-07-26 Univ Rockefeller PROCESS FOR CLASSIFYING ANTIPSYCHOTIC DRUGS

Also Published As

Publication number Publication date
CN1703198A (zh) 2005-11-30
US20040146562A1 (en) 2004-07-29
BR0315663A (pt) 2005-08-30
AR041826A1 (es) 2005-06-01
CA2498276A1 (en) 2004-05-06
JP2006505579A (ja) 2006-02-16
GT200300227A (es) 2004-06-23
NO20051187L (no) 2005-04-11
JP2006219501A (ja) 2006-08-24
NL1024616A1 (nl) 2004-04-27
PL375603A1 (en) 2005-12-12
EP1562546A1 (en) 2005-08-17
PA8586301A1 (es) 2004-05-07
RU2005112202A (ru) 2005-11-20
RU2292207C2 (ru) 2007-01-27
ZA200501979B (en) 2006-04-26
PE20040471A1 (es) 2004-08-14
KR20050071611A (ko) 2005-07-07
NL1024616C (nl) 2010-04-19
AU2003267763A1 (en) 2004-05-13
TW200418477A (en) 2004-10-01
MXPA05004299A (es) 2005-08-03
WO2004037224A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
UY28035A1 (es) Formulaciones de liberacion prolongada en forma de suspension
NO20032889D0 (no) Quinuklidin-karbamat-derivater samt medisinske sammensetninger omfattende slike
TW200626558A (en) Indazolone derivatives
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
CO6501159A2 (es) Formulaciones farmaceuticas de liberación controlada de nitazoxanida
CY2013023I2 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεοσως το ενεργο συστατικο
BRPI0507653A (pt) derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
TW200616976A (en) Pyrimidine derivatives
NO20043937L (no) Anvendelse av vitamin D sammensetninger
AR052233A1 (es) Formulacion liofilizada, estabilizada, para derivados de la cefalosporina
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
MXPA05007484A (es) Derivados de diarilmetilidina piperidina, preparacion y uso de los mismos.
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
SG165404A1 (en) Fulvestrant formulation
IT1320764B1 (it) Uso di composti (per)fluoropolieterei come additivi in formulazioni.
SE0401968D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
UY28856A1 (es) Nuevos imidazoles
DOP2003000730A (es) Formulaciones de liberacion prolongada en forma de suspension
MX2007013327A (es) Formulaciones de liberacion prolongada.
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
DE10341944A1 (de) Antimykotisch wirksame Nagellackformulierung mit substituierten 2-Aminothiazolen als Wirkstoff
ITMI20051273A1 (it) Composizioni in forma di lipogel per uso cosmetico detergente e farmaceutico
AU2003244255A1 (en) Injectable composition comprising ceftiofur sodium as an active ingredient
CO5540291A2 (es) Benzamidoacetonitrilos y su uso como antiparasitarios

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126